

Special Issue

Bone and Soft Tissue Sarcomas: Current Challenges and Future Directions

Message from the Guest Editors

Bone and soft tissue sarcomas are rare cancers that may imply high morbidity and poor disease specific survival despite current treatment modalities. While these tumors typically share a mesenchymal stem cell origin, they are typically characterized by tremendous genetic heterogeneity. For sarcomas as a whole, surgery is generally the mainstay of treatment, though adjuvant therapies typically differ depending on histologic type. For patients with osteosarcoma, chemotherapy dramatically improves survival rates; however, advances in adjuvant treatments have stagnated over the past 30–40 years. For chondrosarcoma, appropriate diagnosis and management continues to be a challenge and a continued subject of debate. In contrast, soft tissue sarcoma is a general term that encompasses over 70 histological subtypes. Radiation therapy is typically a component of the management of these tumors, though novel technologies such as proton beam therapy and carbon ion therapy hold additional promise. Owing to their collective rarity, research on sarcomas is inherently challenging; however, continued collaborative scientific efforts have helped to push the field forward.

Guest Editors

Dr. Alexander L. Lazarides

Sarcoma Department, Moffitt Cancer Center, Tampa, FL, USA

Dr. Odion T. Binitie

Sarcoma Department, Moffitt Cancer Center, Tampa, FL, USA

Deadline for manuscript submissions

closed (28 February 2023)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/121573

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1
(General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).